Search

Your search keyword '"Coene, P. P. L. O."' showing total 35 results
Start Over Author "Coene, P. P. L. O."
35 results on '"Coene, P. P. L. O."'

1. Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort Study

Author

van der Zijden, Charlène J., van der Sluis, Pieter C., Mostert, Bianca, Nuyttens, Joost J. M. E., van Lanschot, J. Jan B., Spaander, Manon C. W., Valkema, Roelf, Coene, Peter Paul L. O., Dekker, Jan Willem T., Fiets, Willem E., Hartgrink, Hendrik H., Hazen, Wouter L., Kouwenhoven, Ewout A., Nieuwenhuijzen, Grard A. P., Rosman, Camiel, van Sandick, Johanna W., Sosef, Meindert N., van der Zaag, Edwin S., Lagarde, Sjoerd M., and Wijnhoven, Bas P. L.

Published
2024
Full Text
View/download PDF

2. Functional outcomes and quality of life following open versus laparoscopic versus robot-assisted versus transanal total mesorectal excision in rectal cancer patients: a systematic review and meta-analysis.

Author

Geitenbeek, Ritch T. J., Burghgraef, Thijs A., Moes, Carmen A., Hompes, Roel, Ranchor, Adelita V., Consten, Esther C. J., van Acker, G. J. D., Aukema, T. S., Belgers, H. J., Beverdam, F. H., Bloemen, J. G., Bosscha, K., Breukink, S. O., Coene, P. P. L. O., Crolla, R. M. P. H., van Duijvendijk, P., van Duyn, E. B., Faneyte, I. F., Fransen, S. A. F., and van Geloven, A. A. W.

Subjects
ABDOMINOPERINEAL resection, SURGICAL robots, URINARY organ physiology, MEDICAL information storage & retrieval systems, FEMALE reproductive organ diseases, LAPAROSCOPIC surgery, TREATMENT effectiveness, META-analysis, CANCER patients, DESCRIPTIVE statistics, RECTUM tumors, SURGICAL complications, SYSTEMATIC reviews, MEDLINE, MALE reproductive organ diseases, ENDOSCOPIC gastrointestinal surgery, QUALITY of life, MEDICAL databases, SEXUAL dysfunction, ONLINE information services, CONFIDENCE intervals, SEXUAL health
Abstract

Background: The standard surgical treatment for rectal cancer is total mesorectal excision (TME), which may negatively affect patients' functional outcomes and quality of life (QoL). However, it is unclear how different TME techniques may impact patients' functional outcomes and QoL. This systematic review and meta-analysis evaluated functional outcomes of urinary, sexual, and fecal functioning as well as QoL after open, laparoscopic (L-TME), robot-assisted (R-TME), and transanal total mesorectal excision (TaTME). Methods: A systematic review and meta-analysis, based on the preferred reporting items for systematic reviews and meta-analysis statement, were conducted (PROSPERO: CRD42021240851). A literature review was performed (sources: PubMed, Medline, Embase, Scopus, Web of Science, and Cochrane Library databases; end-of-search date: September 1, 2023), and a quality assessment was performed using the Methodological index for non-randomized studies. A random-effects model was used to pool the data for the meta-analyses. Results: Nineteen studies were included, reporting on 2495 patients (88 open, 1171 L-TME, 995 R-TME, and 241 TaTME). Quantitative analyses comparing L-TME vs. R-TME showed no significant differences regarding urinary and sexual functioning, except for urinary function at three months post-surgery, which favoured R-TME (SMD [CI] –0.15 [− 0.24 to − 0.06], p = 0.02; n = 401). Qualitative analyses identified most studies did not find significant differences in urinary, sexual, and fecal functioning and QoL between different techniques. Conclusions: This systematic review and meta-analysis highlight a significant gap in the literature concerning the evaluation of functional outcomes and QoL after TME for rectal cancer treatment. This study emphasizes the need for high-quality, randomized-controlled, and prospective cohort studies evaluating these outcomes. Based on the limited available evidence, this systematic review and meta-analysis suggests no significant differences in patients' urinary, sexual, and fecal functioning and their QoL across various TME techniques. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Ten-year outcomes of a randomised trial of laparoscopic versus open surgery for colon cancer

Author

Deijen, Charlotte L., Vasmel, Jeanine E., de Lange-de Klerk, Elly S. M., Cuesta, Miguel A., Coene, Peter-Paul L. O., Lange, Johan F., Meijerink, W. J. H. Jeroen, Jakimowicz, Jack J., Jeekel, Johannes, Kazemier, Geert, Janssen, Ignace M. C., Påhlman, Lars, Haglind, Eva, Bonjer, H. Jaap, Hellberg, R., Haglind, E., Kurlberg, G., Lindgren, P. G., Lindholm, E., Påhlman, L., Dahlberg, M., Raab, Y., Anderberg, B., Ewerth, S., Janson, M., Åkerlund, J. E., Smedh, K., Montgomery, A., Skullman, S., Nyström, P. O., Kald, A., Wänström, A., Dàlen, J., Svedberg, I., Edlund, G., Kressner, U., Öberg, A. N., Lundberg, O., Lindmark, G. E., Heikkinen, T., Morino, M., Giraudo, G., Lacy, A. M., Delgado, S., Macarulla Sanz, E., Díez, J. Medina, Schwandner, O., Schiedeck, T. H., Shekarriz, H., Bloechle, C., Baca, I., Weiss, O., Msika, S., Desvignes, G., Campbell, K. L., Cuschieri, A., Bonjer, H. J., Schouten, W. R., Kazemier, G., Lange, J. F., van der Harst, E., Coene, P. P. L. O., Plaisier, P., Bertleff, M. J. O. E., Cuesta, M. A., van der Broek, W., Meijerink, W. J. H. J., Jakimowicz, J. J., Nieuwenhuijzen, G., Maring, J., Kivit, J., Janssen, I. M. C., Spillenaar-Bilgen, E. J., Berends, F., and On behalf of the COLOR (COlon cancer Laparoscopic or Open Resection) study group

Published
2017
Full Text
View/download PDF

5. Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: a multicentre, parallel-group, randomised, open-label trial

Author

Hop, W C, Opmeer, B C, Reitsma, J B, Scholte, R A, Waltmann, E W H, Legemate, D A, Bartelsman, J F, Meijer, D W, de Brouwer, M, van Dalen, J, Durbridge, M, Geerdink, M, Ilbrink, G J, Mehmedovic, S, Middelhoek, P, Di Saverio, Salomone, Boom, M J, Consten, E C J, van der Bilt, J D W, van Olden, G D J, Stam, M A W, Verweij, M S, Busch, O R C, Buskens, C J, El-Massoudi, Y, Kluit, A B, van Rossem, C C, Schijven, M P, Tanis, P J, Unlu, C, Gerhards, M F, Karsten, T M, de Nes, L C, Rijna, H, van Wagensveld, B A, Koffeman, G I, Steller, E P, Tuynman, J B, Bruin, S C, van der Peet, D L, Blanken-Peeters, C F J M, Cense, H A, Jutte, E, Crolla, R M P H, van der Schelling, G P, van Zeeland, M, de Graaf, E J R, Groenendijk, R P R, Vermaas, M, Schouten, O, de Vries, M R, Prins, H A, Lips, D J, Bosker, R J I, van der Hoeven, J A B, Diks, J, Plaisier, P W, Kruyt, P M, Sietses, C, Stommel, M W J, Nienhuijs, S W, de Hingh, I H J T, Luyer, M D P, van Montfort, G, Ponten, E H, Smulders, J F, van Duyn, E B, Klaase, J M, Swank, D J, Ottow, R T, Stockmann, H B A C, Vermeulen, J, Vuylsteke, R J C L M, Belgers, H J, Fransen, S, von Meijenfeldt, E M, Sosef, M N, van Geloven, A A W, Hendriks, E R, ter Horst, B, Leeuwenburgh, M M N, van Ruler, O, Vogten, J M, Vriens, E J C, Westerterp, M, Eijsbouts, Q A J, Bentohami, A, Bijlsma, T S, de Korte, N, Nio, D, Govaert, M J P M, Joosten, J J A, Tollenaar, R A E M, Stassen, L P S, Wiezer, M J, Hazebroek, E J, Smits, A B, van Westreenen, H L, Lange, J F, Brandt, A, Nijboer, W N, Toorenvliet, B R, Weidema, W F, Coene, P P L O, Mannaerts, G H H, den Hartog, D, de Vos, R J, Zengerink, J F, Hoofwijk, A G M, Hulsewé, K W E, Melenhorst, J, Stoot, J H M B, Steup, W H, Huijstee, P J, Merkus, J W S, Wever, J J, Maring, J K, Heisterkamp, J, van Grevenstein, W M U, Vriens, M R, Besselink, M G H, Borel Rinkes, I H M, Witkamp, A J, Slooter, G D, Konsten, J L M, Engel, A F, Pierik, E G J M, Frakking, T G, van Geldere, D, Patijn, G A, D'Hoore, A J L, de Buck van Overstraeten, A, Miserez, M, Terrasson, I, Wolthuis, A, De Blasiis, M G, Vennix, Sandra, Musters, Gijsbert D, Mulder, Irene M, Swank, Hilko A, Consten, Esther C, Belgers, Eric H, van Geloven, Anna A, Gerhards, Michael F, Govaert, Marc J, van Grevenstein, Wilhelmina M, Hoofwijk, Anton G, Kruyt, Philip M, Nienhuijs, Simon W, Boermeester, Marja A, Vermeulen, Jefrey, van Dieren, Susan, Lange, Johan F, and Bemelman, Willem A

Published
2015
Full Text
View/download PDF

6. The influence of hospital volume on long-term oncological outcome after rectal cancer surgery

Author

Jonker, Frederik H. W., Hagemans, Jan A. W., Burger, Jacobus W. A., Verhoef, Cornelis, Borstlap, Wernard A. A., Tanis, Pieter J., Aalbers, A., Acherman, Y., Algie, G. D., Alting von Geusau, B., Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bemelman, W. A., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Clermonts, S., Coene, P. P. L. O., Compaan, C., Consten, E. C. J., Darbyshire, T., de Mik, S. M. L., de Graaf, E. J. R., de Groot, I., de vos tot Nederveen Cappel, R. J. L., de Wilt, J. H. W., van der Wolde, J., den Boer, F. C., Dekker, J. W. T., Demirkiran, A., Derkx-Hendriksen, M., Dijkstra, F. R., van Duijvendijk, P., Dunker, M. S., Eijsbouts, Q. E., Fabry, H., Ferenschild, F., Foppen, J. W., Furnée, E. J. B., Gerhards, M. F., Gerven, P., Gooszen, J. A. H., Govaert, J. A., Van Grevenstein, W. M. U., Haen, R., Harlaar, J. J., Harst, E., Havenga, K., Heemskerk, J., Heeren, J. F., Heijnen, B., Heres, P., Hoff, C., Hogendoorn, W., Hoogland, P., Huijbers, A., Gooszen, J. A. H., Janssen, P., Jongen, A. C., Karthaus, E. G., Keijzer, A., Ketel, J. M. A., Klaase, J., Kloppenberg, F. W. H., Kool, M. E., Kortekaas, R., Kruyt, P. M., Kuiper, J. T., Lamme, B., Lange, J. F., Lettinga, T., Lips, D. J., Logeman, F., Lutke Holzik, M. F., Madsen, E., Mamound, A., Marres, C. C., Masselink, I., Meerdink, M., Menon, A. G., Mieog, J. S., Mierlo, D., Musters, G. D., Neijenhuis, P. A., Nonner, J., Oostdijk, M., Oosterling, S. J., Paul, P. M. P., Peeters, K. C. M. J. C., Pereboom, I. T. A., Polat, F., Poortman, P., Raber, M., Reiber, B. M. M., Renger, R. J., van Rossem, C. C., Rutten, H. J., Rutten, A., Schaapman, R., Scheer, M., Schoonderwoerd, L., Schouten, N., Schreuder, A. M., Schreurs, W. H., Simkens, G. A., Slooter, G. D., Sluijmer, H. C. E., Smakman, N., Smeenk, R., Snijders, H. S., Sonneveld, D. J. A., Spaansen, B., Spillenaar Bilgen, E. J., Steller, E., Steup, W. H., Steur, C., Stortelder, E., Straatman, J., Swank, H. A., Sietses, C., ten Berge, H. A., ten hoeve, H. G., ter Riele, W. W., Thorensen, I. M., Tip-Pluijm, B., Toorenvliet, B. R., Tseng, L., Tuynman, J. B., van Bastelaar, J., van beek, S. C., van de Ven, A. W. H., van de Weijer, M. A. J., van den Berg, C., van den Bosch, I., van der Bilt, J. D. W., van der Hagen, S. J., van der hul, R., van der Schelling, G., van der Spek, A., van der Wielen, N., van duyn, E., van Eekelen, C., van Essen, J. A., van Gangelt, K., van Geloven, A. A. W., van kessel, C., van Loon, Y. T., van Rijswijk, A., van Rooijen, S. J., van Sprundel, T., van Steensel, L., van Tets, W. F., van Westreenen, H. L., Veltkamp, S., Verhaak, T., Verheijen, P. M., Versluis-Ossenwaarde, L., Vijfhuize, S., Vles, W. J., Voeten, S., Vogelaar, F. J., Vrijland, W. W., Westerduin, E., Westerterp, M. E., Wetzel, M., Wevers, K., Wiering, B., Witjes, A. C., Wouters, M. W., Yauw, S. T. K., Zeestraten, E. C., Zimmerman, D. D., Zwieten, T., and Dutch Snapshot Research Group

Published
2017
Full Text
View/download PDF

8. Does oncological outcome differ between restorative and nonrestorative low anterior resection in patients with primary rectal cancer?

Author

Roodbeen, Sapho X., Blok, Robin D., Borstlap, Wernard A., Bemelman, Willem A., Hompes, Roel, Tanis, Pieter J., Aalbers, A. G. J., Acherman, Y., Algie, G. D., Alting von Geusau, B., Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Burger, J. W. A., Buskens, C. J., Clermonts, S., Coene, P. P. L. O., Compaan, C., Consten, E. C. J., Darbyshire, T., de Mik, S. M. L., van Duijvendijk, P., Gooszen, J. A. H., Hoogland, P., Lamme, B., Marres, C. C., Musters, G. D., van Rossem, C. C., Schreuder, A. M., Swank, H. A., Tuynman, J. B., van Beek, S. C., van Westreenen, H. L., Westerduin, E., ​Robotics and image-guided minimally-invasive surgery (ROBOTICS), Graduate School, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Center of Experimental and Molecular Medicine, Surgery, 02 Surgical specialisms, Tytgat Institute for Liver and Intestinal Research, APH - Personalized Medicine, and APH - Quality of Care

Subjects
medicine.medical_specialty, SURGERY, Colorectal cancer, MULTICENTER, Urology, Anastomosis, MESORECTAL EXCISION, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, rectal surgery, Medicine, In patient, Survival analysis, Low Anterior Resection, Neoplasia, oncological outcome, business.industry, Proportional hazards model, Gastroenterology, Original Articles, low anterior resection, medicine.disease, Dissection, 030220 oncology & carcinogenesis, Original Article, 030211 gastroenterology & hepatology, local recurrence, Outcome data, business, RADIOTHERAPY
Abstract

Contains fulltext : 239366.pdf (Publisher’s version ) (Open Access) AIM: Nonrestorative low anterior resection (n-rLAR) (also known as low Hartmann's) is performed for rectal cancer when a poor functional outcome is anticipated or there have been problems when constructing the anastomosis. Compared with restorative LAR (rLAR), little oncological outcome data are available for n-rLAR. The aim of this study was to compare oncological outcomes between rLAR and n-rLAR for primary rectal cancer. METHOD: This was a nationwide cross-sectional comparative study including all elective sphincter-saving LAR procedures for nonmetastatic primary rectal cancer performed in 2011 in 71 Dutch hospitals. Oncological outcomes of patients undergoing rLAR and n-rLAR were collected in 2015; the data were evaluated using Kaplan-Meier survival analysis and the results compared using log-rank testing. Uni- and multivariable Cox regression analysis was used to evaluate the association between the type of LAR and oncological outcome measures. RESULTS: A total of 1197 patients were analysed, of whom 892 (75%) underwent rLAR and 305 (25%) underwent n-rLAR. The 3-year local recurrence (LR) rate was 3% after rLAR and 8% after n-rLAR (P

Published
2020
Full Text
View/download PDF

9. Prognostic importance of lymph node count and ratio in rectal cancer after neoadjuvant chemoradiotherapy: Results from a cross-sectional study

Author

Detering, Robin, Meyer, Vincent M., Borstlap, Wernard A. A., Beets-Tan, Regina G. H., Marijnen, Corrie A. M., Hompes, Roel, Tanis, Pieter J., van Westreenen, Henderik L., Aalbers, A. G. J., Acherman, Y., Algie, G. D., Alting von Geusau, B., Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Burger, J. W. A., Buskens, C. J., Clermonts, S., Coene, P. P. L. O., Compaan, C., de Mik, S. M. L., van Duijvendijk, P., Gooszen, J. A. H., Hoogland, P., Lamme, B., Marres, C. C., Musters, G. D., van Rossem, C. C., Schreuder, A. M., Swank, H. A., Tuynman, J. B., van Beek, S. C., van Westreenen, H. L., Westerduin, E., Surgery, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, AGEM - Endocrinology, metabolism and nutrition, CCA - Cancer Treatment and quality of life, Anatomy and neurosciences, General practice, VU University medical center, Obstetrics and gynaecology, and Amsterdam Reproduction & Development (AR&D)

Subjects
Oncology, medicine.medical_specialty, disease-free survival, Colorectal cancer, Cross-sectional study, survival, chemoradiotherapy, 03 medical and health sciences, 0302 clinical medicine, lymph nodes, Internal medicine, Medicine, Humans, Stage (cooking), rectal cancer, Lymph node, Neoplasm Staging, Netherlands, Retrospective Studies, business.industry, Rectal Neoplasms, General Medicine, medicine.disease, Prognosis, Total mesorectal excision, Neoadjuvant Therapy, Survival Rate, medicine.anatomical_structure, Cross-Sectional Studies, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Cohort, Multivariate Analysis, 030211 gastroenterology & hepatology, Surgery, business, Chemoradiotherapy, Neoadjuvant chemoradiotherapy
Abstract

Background: The aim of this study was to determine the prognostic value of lymph node count (LNC) and lymph node ratio (LNR) in rectal cancer after neoadjuvant chemoradiotherapy (CRT). Methods: Patients who underwent neoadjuvant CRT and total mesorectal excision (TME) for Stage I–III rectal cancer were selected from a cross-sectional study including 71 Dutch centres. Primary outcome parameters were disease-free survival (DFS) and overall survival (OS). Prognostic significance of LNC and LNR (cut-off values 0.15, 0.20, 0.30) was tested for different (sub)groups. Results: From 2095 registered patients, 458 were included, of which 240 patients with LNC < 12 and 218 patients with LNC ≥ 12. LNC was not significantly associated with DFS (p = 0.35) and OS (p = 0.59). In univariable analysis, LNR was significantly associated with DFS and OS in the whole cohort and LNC subgroups, but not in multivariable analysis. Conclusions: LNC was not associated with long-term oncological outcome in rectal cancer patients treated with CRT, nor was LNR when corrected for N-stage. However, LNR might be used to identify subgroups of node-positive patients with a favourable outcome.

Published
2021
Full Text
View/download PDF

11. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial):study protocol for a nationwide multicenter randomized controlled trial

Author

Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., De Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y., van Tienhoven, G., Besselink, M. G., Wilmink, J. W., Koerkamp, B. Groot, Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., De Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y., van Tienhoven, G., Besselink, M. G., Wilmink, J. W., and Koerkamp, B. Groot

Abstract

BackgroundNeoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients.MethodsThis nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is defined as no arterial and <= 90 degrees venous involvement; borderline resectable pancreatic cancer is defined as <= 90 degrees arterial and <= 270 degrees venous involvement without occlusion. Patients receive 8cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36Gy in 15 fractions) during the second cycle, followed by surgery and 4cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after inclusion of 368 eligible patients as

Published
2021

16. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.

Author

Janssen, Q. P., van Dam, J. L., Bonsing, B. A., Bos, H., Bosscha, K. P., Coene, P. P. L. O., van Eijck, C. H. J., de Hingh, I. H. J. T., Karsten, T. M., van der Kolk, M. B., Patijn, G. A., Liem, M. S. L., van Santvoort, H. C., Loosveld, O. J. L., de Vos-Geelen, J., Zonderhuis, B. M., Homs, M. Y. V., van Tienhoven, G., Besselink, M. G., and Wilmink, J. W.

Subjects
PANCREATIC cancer, CHEMORADIOTHERAPY, PANCREATIC surgery, QUALITY of life, NEOADJUVANT chemotherapy, PROGRESSION-free survival, CANCER patients
Abstract

Background: Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients undergo futile surgery, and R0 resection rates are higher, thereby possibly improving overall survival (OS). Two recent randomized trials have suggested benefit of neoadjuvant chemoradiotherapy over upfront surgery, both including single-agent chemotherapy regimens. Potentially, the multi-agent FOLFIRINOX regimen (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) may further improve outcomes in the neoadjuvant setting for localized pancreatic cancer, but randomized studies are needed. The PREOPANC-2 trial investigates whether neoadjuvant FOLFIRINOX improves OS compared with neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer patients.Methods: This nationwide multicenter phase III randomized controlled trial includes patients with pathologically confirmed resectable and borderline resectable pancreatic cancer with a WHO performance score of 0 or 1. Resectable pancreatic cancer is defined as no arterial and ≤ 90 degrees venous involvement; borderline resectable pancreatic cancer is defined as ≤90 degrees arterial and ≤ 270 degrees venous involvement without occlusion. Patients receive 8 cycles of neoadjuvant FOLFIRINOX chemotherapy followed by surgery without adjuvant treatment (arm A), or 3 cycles of neoadjuvant gemcitabine with hypofractionated radiotherapy (36 Gy in 15 fractions) during the second cycle, followed by surgery and 4 cycles of adjuvant gemcitabine (arm B). The primary endpoint is OS by intention-to-treat. Secondary endpoints include progression-free survival, quality of life, resection rate, and R0 resection rate. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after inclusion of 368 eligible patients assuming an accrual period of 3 years and 1.5 years follow-up.Discussion: The PREOPANC-2 trial directly compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer. Our study will provide evidence on the neoadjuvant treatment of choice for patients with resectable and borderline resectable pancreatic cancer.Trial Registration: Primary registry and trial identifying number: EudraCT: 2017-002036-17 . Date of registration: March 6, 2018. Secondary identifying numbers: The Netherlands National Trial Register - NL7094 , NL61961.078.17, MEC-2018-004. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

17. Nationwide comprehensive gastro-intestinal cancer cohorts : The 3P initiative

Author

van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., van Laarhoven, H. W. M., van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and van Laarhoven, H. W. M.

Published
2018

18. Nationwide comprehensive gastro-intestinal cancer cohorts: The 3P initiative

Author

Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, MS CGO, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., van Laarhoven, H. W. M., Cancer, Onderzoek Medische Oncologie, MS Medische Oncologie, MS CGO, Trialbureau Beeld, Epi Kanker Team A, Circulatory Health, JC onderzoeksprogramma Kanker, van den Braak, R. R. J. Coebergh, van Rijssen, L. B., van Kleef, J. J., Vink, G. R., Berbee, M., Henegouwen, M. I. van Berge, Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupe, V. M. H., Dekker, J. W. T., van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., van Grevenstein, W. M. U., de Groot, J. W. B., van Grieken, N. C. T., de Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., de Noo, M. E., van de Poll-Franse, L. V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., van Tienhoven, G., Timmermans, L. M., Tjin-a-Ton, M. L. R., van der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., de Vos-Geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and van Laarhoven, H. W. M.

Published
2018

19. Nationwide comprehensive gastro-intestinal cancer cohorts: The 3P initiative

Author

Coebergh Van Den Braak, R. R. J., Van Rijssen, L. B., Van Kleef, J. J., Vink, G. R., Berbee, M., Van Berge Henegouwen, M. I., Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupé, V. M. H., Dekker, J. W. T., Van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., Van Grevenstein, W. M. U., De Groot, J. W. B., Van Grieken, N. C. T., De Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., De Noo, M. E., van de Poll-Franse, L.V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., Van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., Van Tienhoven, G., Timmermans, L. M., Tjin-a-ton, M. L. R., Van Der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., De Vos-geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., Van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., Van Laarhoven, H. W. M., Coebergh Van Den Braak, R. R. J., Van Rijssen, L. B., Van Kleef, J. J., Vink, G. R., Berbee, M., Van Berge Henegouwen, M. I., Bloemendal, H. J., Bruno, M. J., Burgmans, M. C., Busch, O. R. C., Coene, P. P. L. O., Coupé, V. M. H., Dekker, J. W. T., Van Eijck, C. H. J., Elferink, M. A. G., Erdkamp, F. L. G., Van Grevenstein, W. M. U., De Groot, J. W. B., Van Grieken, N. C. T., De Hingh, I. H. J. T., Hulshof, M. C. C. M., Ijzermans, J. N. M., Kwakkenbos, L., Lemmens, V. E. P. P., Los, M., Meijer, G. A., Molenaar, I. Q., Nieuwenhuijzen, G. A. P., De Noo, M. E., van de Poll-Franse, L.V., Punt, C. J. A., Rietbroek, R. C., Roeloffzen, W. W. H., Rozema, T., Ruurda, J. P., Van Sandick, J. W., Schiphorst, A. H. W., Schipper, H., Siersema, P. D., Slingerland, M., Sommeijer, D. W., Spaander, M. C. W., Sprangers, M. A. G., Stockmann, H. B. A. C., Strijker, M., Van Tienhoven, G., Timmermans, L. M., Tjin-a-ton, M. L. R., Van Der Velden, A. M. T., Verhaar, M. J., Verkooijen, H. M., Vles, W. J., De Vos-geelen, J. M. P. G. M., Wilmink, J. W., Zimmerman, D. D. E., Van Oijen, M. G. H., Koopman, M., Besselink, M. G. H., and Van Laarhoven, H. W. M.

Abstract

Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients.Material and methods: All patients aged 18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future.Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing.Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses

Published
2018

21. Benchmarking recent national practice in rectal cancer treatment with landmark randomized controlled trials

Author

Borstlap, W. A. A., Borstlap, W. A. A., Deijen, C. L., den Dulk, M., Bonjer, H. J., van de Velde, C. J., Bemelman, W. A., Tanis, P. J., Aalbers, A., Acherman, Y., Algie, G. D., von Geu-sau, B. Alting, Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Burger, J. W. A., Buskens, C. J., Clermonts, S., Coene, P. P. L. O., Compaan, C., Consten, E. C. J., Darbyshire, T., de Mik, S. M. L., de Groot, I., Heemskerk, J., Heijnen, B., Hoogland, P., Jongen, A. C., Kool, M. E., van Rossem, C. C., Rutten, H. J., Schouten, N., Simkens, G. A., Wetzel, M., Wouters, M. W., Dutch Snapshot Res Grp, Borstlap, W. A. A., Borstlap, W. A. A., Deijen, C. L., den Dulk, M., Bonjer, H. J., van de Velde, C. J., Bemelman, W. A., Tanis, P. J., Aalbers, A., Acherman, Y., Algie, G. D., von Geu-sau, B. Alting, Amelung, F., Aukema, T. S., Bakker, I. S., Bartels, S. A., Basha, S., Bastiaansen, A. J. N. M., Belgers, E., Bleeker, W., Blok, J., Bosker, R. J. I., Bosmans, J. W., Boute, M. C., Bouvy, N. D., Bouwman, H., Brandt-Kerkhof, A., Brinkman, D. J., Bruin, S., Bruns, E. R. J., Burbach, J. P. M., Burger, J. W. A., Buskens, C. J., Clermonts, S., Coene, P. P. L. O., Compaan, C., Consten, E. C. J., Darbyshire, T., de Mik, S. M. L., de Groot, I., Heemskerk, J., Heijnen, B., Hoogland, P., Jongen, A. C., Kool, M. E., van Rossem, C. C., Rutten, H. J., Schouten, N., Simkens, G. A., Wetzel, M., Wouters, M. W., and Dutch Snapshot Res Grp

Abstract

Aim A Snapshot study design eliminates changes in treatment and outcome over time. This population based Snapshot study aimed to determine current practice and outcome of rectal cancer treatment with published landmark randomized controlled trials as a benchmark.Method In this collaborative research project, the dataset of the Dutch Surgical Colorectal Audit was extended with additional treatment and long-term outcome data. All registered patients who underwent resection for rectal cancer in 2011 were eligible. Baseline characteristics and outcome were evaluated against the results of the Dutch TME trial and the COLOR II trial from which the original datasets were obtained.Results A total of 71 hospitals participated, and data were completed for 2102 out of the potential 2633 patients (79.8%). Median follow-up was 41 (interquartile range 25-47) months. Overall circumferential resection margin (CRM) involvement was 9.3% in the Snapshot cohort and 18.5% in the Dutch TME trial. CRM positivity after laparoscopic resection was 7.8% in the Snapshot and 9.5% in the COLOR II trial. Three-year overall local recurrence rate in the Snapshot was 5.9%, with a disease-free survival of 67.1% and overall survival of 79.5%. Benchmarking with the randomized controlled trials revealed an overall favourable long-term outcome of the Snapshot cohort.Conclusion This study showed that current rectal cancer care in a large unselected Dutch population is of high quality, with less positive CRM since the TME trial and oncologically safe implementation of minimally invasive surgery after the COLOR II trial.

Published
2017

22. Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: a multicentre, parallel-group, randomised, open-label trial

Author

Vennix, Sandra, primary, Musters, Gijsbert D, additional, Mulder, Irene M, additional, Swank, Hilko A, additional, Consten, Esther C, additional, Belgers, Eric H, additional, van Geloven, Anna A, additional, Gerhards, Michael F, additional, Govaert, Marc J, additional, van Grevenstein, Wilhelmina M, additional, Hoofwijk, Anton G, additional, Kruyt, Philip M, additional, Nienhuijs, Simon W, additional, Boermeester, Marja A, additional, Vermeulen, Jefrey, additional, van Dieren, Susan, additional, Lange, Johan F, additional, Bemelman, Willem A, additional, Hop, W C, additional, Opmeer, B C, additional, Reitsma, J B, additional, Scholte, R A, additional, Waltmann, E W H, additional, Legemate, D A, additional, Bartelsman, J F, additional, Meijer, D W, additional, de Brouwer, M, additional, van Dalen, J, additional, Durbridge, M, additional, Geerdink, M, additional, Ilbrink, G J, additional, Mehmedovic, S, additional, Middelhoek, P, additional, Di Saverio, Salomone, additional, Boom, M J, additional, Consten, E C J, additional, van der Bilt, J D W, additional, van Olden, G D J, additional, Stam, M A W, additional, Verweij, M S, additional, Busch, O R C, additional, Buskens, C J, additional, El-Massoudi, Y, additional, Kluit, A B, additional, van Rossem, C C, additional, Schijven, M P, additional, Tanis, P J, additional, Unlu, C, additional, Gerhards, M F, additional, Karsten, T M, additional, de Nes, L C, additional, Rijna, H, additional, van Wagensveld, B A, additional, Koffeman, G I, additional, Steller, E P, additional, Tuynman, J B, additional, Bruin, S C, additional, van der Peet, D L, additional, Blanken-Peeters, C F J M, additional, Cense, H A, additional, Jutte, E, additional, Crolla, R M P H, additional, van der Schelling, G P, additional, van Zeeland, M, additional, de Graaf, E J R, additional, Groenendijk, R P R, additional, Vermaas, M, additional, Schouten, O, additional, de Vries, M R, additional, Prins, H A, additional, Lips, D J, additional, Bosker, R J I, additional, van der Hoeven, J A B, additional, Diks, J, additional, Plaisier, P W, additional, Kruyt, P M, additional, Sietses, C, additional, Stommel, M W J, additional, Nienhuijs, S W, additional, de Hingh, I H J T, additional, Luyer, M D P, additional, van Montfort, G, additional, Ponten, E H, additional, Smulders, J F, additional, van Duyn, E B, additional, Klaase, J M, additional, Swank, D J, additional, Ottow, R T, additional, Stockmann, H B A C, additional, Vermeulen, J, additional, Vuylsteke, R J C L M, additional, Belgers, H J, additional, Fransen, S, additional, von Meijenfeldt, E M, additional, Sosef, M N, additional, van Geloven, A A W, additional, Hendriks, E R, additional, ter Horst, B, additional, Leeuwenburgh, M M N, additional, van Ruler, O, additional, Vogten, J M, additional, Vriens, E J C, additional, Westerterp, M, additional, Eijsbouts, Q A J, additional, Bentohami, A, additional, Bijlsma, T S, additional, de Korte, N, additional, Nio, D, additional, Govaert, M J P M, additional, Joosten, J J A, additional, Tollenaar, R A E M, additional, Stassen, L P S, additional, Wiezer, M J, additional, Hazebroek, E J, additional, Smits, A B, additional, van Westreenen, H L, additional, Lange, J F, additional, Brandt, A, additional, Nijboer, W N, additional, Toorenvliet, B R, additional, Weidema, W F, additional, Coene, P P L O, additional, Mannaerts, G H H, additional, den Hartog, D, additional, de Vos, R J, additional, Zengerink, J F, additional, Hoofwijk, A G M, additional, Hulsewé, K W E, additional, Melenhorst, J, additional, Stoot, J H M B, additional, Steup, W H, additional, Huijstee, P J, additional, Merkus, J W S, additional, Wever, J J, additional, Maring, J K, additional, Heisterkamp, J, additional, van Grevenstein, W M U, additional, Vriens, M R, additional, Besselink, M G H, additional, Borel Rinkes, I H M, additional, Witkamp, A J, additional, Slooter, G D, additional, Konsten, J L M, additional, Engel, A F, additional, Pierik, E G J M, additional, Frakking, T G, additional, van Geldere, D, additional, Patijn, G A, additional, D'Hoore, A J L, additional, de Buck van Overstraeten, A, additional, Miserez, M, additional, Terrasson, I, additional, Wolthuis, A, additional, and De Blasiis, M G, additional

Published
2015
Full Text
View/download PDF

23. Completeness of pathology reports in stage II colorectal cancer.

Author

Büttner, Stefan, Lalmahomed, Zarina S., van den Braak, Robert R. J. Coebergh, Hansen, Bettina E., Coene, Peter Paul L. O., Dekker, Jan Willem T., Zimmerman, David D. E., Tetteroo, Geert W. M., Vles, Wouter J., Vrijland, Wietske W., Fleischeuer, Ruth E. M., van der Wurff, Anneke A. M., Kliffen, Mike, Torenbeek, Rolf, Meijers, J. H. Carel, Doukas, Michael, and IJzermans, Jan N. M.

Published
2017
Full Text
View/download PDF

24. Comparison of a low Hartmann's procedure with low colorectal anastomosis with and without defunctioning ileostomy after radiotherapy for rectal cancer: results from a national registry.

Author

Jonker, F. H. W., Tanis, P. J., Coene, P. P. L. O., Gietelink, L., Harst, E., Aalbers, A. G, Bemelman, W. A., Boerma, D., Dam, R. M., Dekker, J. W., Eddes, E. H., Elferink, M. A, Graaf, E. J. R., Karsten, T. M., Krieken, H., Lemmens, V. E. P. P., Manusama, E. R., Meijerink, W. J. H. J., Noo, M. E., and Rutten, H. J. T.

Subjects
OPERATIVE surgery, SURGICAL anastomosis, RECTAL cancer treatment, CANCER radiotherapy complications, ILEOSTOMY, SURGICAL excision, SURGICAL complications
Abstract

Aim This study used a national registry to compare the outcome after a low Hartmann's procedure ( LHP), defined as removal of most of the rectum to leave a short anorectal stump and an end colostomy, and low anterior resection (LA) with or without a diverting ileostomy ( DI) in rectal cancer patients all of whom had received preoperative neoadjuvant radiotherapy ( RT). Method Patients who underwent LHP or LA with or without DI for rectal cancer after RT between 2009 and 2013 were identified from the Dutch Surgical Colorectal Audit. The postoperative outcome was compared between the three groups and risk of complications, reoperation and mortality were analysed in a multivariable model. Results The study included 4288 patients were included, of whom 27.8% underwent LHP, 20.2% LA and 52.0% LA with DI. Thirty-day mortality was higher after LHP (3.2% vs 1.3% and 1.3% for LA with or without DI, P < 0.001), but LHP was not an independent predictor of mortality in multivariable analysis. LHP and LA with DI were associated with a lower rate of abdominal infective complications (6.5% and 10.1% vs 16.2%, P < 0.001) and reoperation (7.3% and 8.1% vs 16.5%, P < 0.001). In multivariable analysis, LHP ( OR 0.35, 95% CI 0.26-0.47) and LA with DI ( OR 0.43, 95% CI 0.33-0.54) were associated with a lower risk of reoperation than LA alone. LHP was associated with a lower risk of any postoperative complication than LA with or without DI ( OR 0.81, 95% CI 0.66-0.98). Conclusion LHP and LA with DI were associated with fewer infective complications and reoperations than LA alone. The rate of any complication was less after LHR than LA with or without DI. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

25. Management of Severe Pancreatic Fistula After Pancreatoduodenectomy

Author

Smits, F. Jasmijn, van Santvoort, Hjalmar C., Besselink, Marc G., Batenburg, Marilot C. T., Slooff, Robbert A. E., Boerma, Djamila, Busch, Olivier R., Coene, Peter P. L. O., van Dam, Ronald M., van Dijk, David P. J., van Eijck, Casper H. J., Festen, Sebastiaan, van der Harst, Erwin, de Hingh, Ignace H. J. T., de Jong, Koert P., Tol, Johanna A. M. G., Borel Rinkes, Inne H. M., and Molenaar, I. Quintus

Abstract

IMPORTANCE: Postoperative pancreatic fistula is a potentially life-threatening complication after pancreatoduodenectomy. Evidence for best management is lacking. OBJECTIVE: To evaluate the clinical outcome of patients undergoing catheter drainage compared with relaparotomy as primary treatment for pancreatic fistula after pancreatoduodenectomy. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, retrospective, propensity-matched cohort study was conducted in 9 centers of the Dutch Pancreatic Cancer Group from January 1, 2005, to September 30, 2013. From a cohort of 2196 consecutive patients who underwent pancreatoduodenectomy, 309 patients with severe pancreatic fistula were included. Propensity score matching (based on sex, age, comorbidity, disease severity, and previous reinterventions) was used to minimize selection bias. Data analysis was performed from January to July 2016. EXPOSURES: First intervention for pancreatic fistula: catheter drainage or relaparotomy. MAIN OUTCOMES AND MEASURES: Primary end point was in-hospital mortality; secondary end points included new-onset organ failure. RESULTS: Of the 309 patients included in the analysis, 209 (67.6%) were men, and mean (SD) age was 64.6 (10.1) years. Overall in-hospital mortality was 17.8% (55 patients): 227 patients (73.5%) underwent primary catheter drainage and 82 patients (26.5%) underwent primary relaparotomy. Primary catheter drainage was successful (ie, survival without relaparotomy) in 175 patients (77.1%). With propensity score matching, 64 patients undergoing primary relaparotomy were matched to 64 patients undergoing primary catheter drainage. Mortality was lower after catheter drainage (14.1% vs 35.9%; P = .007; risk ratio, 0.39; 95% CI, 0.20-0.76). The rate of new-onset single-organ failure (4.7% vs 20.3%; P = .007; risk ratio, 0.15; 95% CI, 0.03-0.60) and new-onset multiple-organ failure (15.6% vs 39.1%; P = .008; risk ratio, 0.40; 95% CI, 0.20-0.77) were also lower after primary catheter drainage. CONCLUSIONS AND RELEVANCE: In this propensity-matched cohort, catheter drainage as first intervention for severe pancreatic fistula after pancreatoduodenectomy was associated with a better clinical outcome, including lower mortality, compared with primary relaparotomy.

Published
2017
Full Text
View/download PDF

28. Primary Closure of the Skin after Stoma Closure.

Author

Vermulst, N., Vermeulen, J., Hazebroek, E. J., Coene, P. P. L. O., and van der Harst, E.

Subjects
SOMATIC sensation, SKIN infections, NOSOCOMIAL infections, ADRENOCORTICAL hormones, ILEOSTOMY complications
Abstract

Background and Aims: Whether or not the skin can be closed primarily after stoma closure is still debated in the existing literature. Therefore, this present study was undertaken to compare the complications and consequences between primary or delayed closure of the skin after stoma closure. Patients and Methods: All consecutive stoma closures between January 2001 and August 2004 were included. In 25 patients (group I), the skin at the stoma site was closed primarily. In 37 patients (group II), the skin was left open. Patient characteristics, comorbidity, medication use, hospital stay and long-term complications were recorded and retrospectively compared between the two groups. Results: In group I, wound infection rate was 36% versus 5% in group II (p = 0.005). Infected wounds were mostly found after ileostomy closure with primary closure of the skin (p = 0.018). The occurrence of a wound infection was not related to the use of corticosteroids, diabetes mellitus, fistula formation, anastomotic leakage, or primary disease and did not lead to a prolonged hospital stay or an increased number of incisional hernias. Conclusion: In our opinion, it is safe to close the skin after stoma closure, but patients should be informed carefully about the advantages and disadvantages of this strategy, especially in case of ileostomy closure. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

31. Herniation of the gall bladder through the abdominal wall.

Author

Pijpers, M., Hazebroek, E. J., Coene, P. P. L. O., Beerman, H., and Vroegindeweij, D.

Subjects
ABDOMINAL muscles, ABDOMINAL wall, SOCIAL conditions of women, MEDICAL imaging systems, GALLBLADDER diseases, ABDOMINAL diseases
Abstract

We present a case of an 81-year-old woman, without medical history, with a swelling in the right lateral abdominal wall. Ultrasound and multislice CT were sufficient to confirm the diagnosis of a herniated gall bladder through the abdominal wall. This is the first case in which MRI proved to be a useful modality to exclude malignant characteristics and revealed an accurate differentiation between the gall bladder and the different layers of the abdominal wall. The gall bladder, including three stones, was removed laparoscopically. Histopathological research revealed signs of a chronic cholecystitis. Herniation of the gall bladder through the abdominal wall is rare. It was previously described in a few cases, but they were associated with the presence of an incisional hernia or carcinoma infiltration. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

35. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative.

Author

Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI, Bloemendal HJ, Bruno MJ, Burgmans MC, Busch ORC, Coene PPLO, Coupé VMH, Dekker JWT, van Eijck CHJ, Elferink MAG, Erdkamp FLG, van Grevenstein WMU, de Groot JWB, van Grieken NCT, de Hingh IHJT, Hulshof MCCM, Ijzermans JNM, Kwakkenbos L, Lemmens VEPP, Los M, Meijer GA, Molenaar IQ, Nieuwenhuijzen GAP, de Noo ME, van de Poll-Franse LV, Punt CJA, Rietbroek RC, Roeloffzen WWH, Rozema T, Ruurda JP, van Sandick JW, Schiphorst AHW, Schipper H, Siersema PD, Slingerland M, Sommeijer DW, Spaander MCW, Sprangers MAG, Stockmann HBAC, Strijker M, van Tienhoven G, Timmermans LM, Tjin-A-Ton MLR, van der Velden AMT, Verhaar MJ, Verkooijen HM, Vles WJ, de Vos-Geelen JMPGM, Wilmink JW, Zimmerman DDE, van Oijen MGH, Koopman M, Besselink MGH, and van Laarhoven HWM

Subjects
Biological Specimen Banks, Cohort Studies, Humans, Registries, Gastrointestinal Neoplasms, Observational Studies as Topic methods, Randomized Controlled Trials as Topic methods, Research Design
Abstract

Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial designs, require innovative research designs. We present the design, governance and current standing of three comprehensive nationwide cohorts including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146). Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome (PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial designs and facilitates research to improve outcomes of gastrointestinal cancer patients., Material and Methods: All patients aged ≥18 years with pancreatic, esophageal/gastric or colorectal cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identified genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new interventional studies and possible participation in cohort multiple randomized controlled trials (cmRCT) in the future., Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from 1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for PROs was 90%. The consent rate to receive information on new interventional studies and possible participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts is steadily increasing., Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies can be performed in an efficient, safe, and comprehensive setting.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results